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ORIGINAL INVESTIGATION
Glucose intolerance after chronic stress 
is related with downregulated PPAR-γ in adipose 
tissue
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Abstract 
Background: Chronic stress is associated with increased risk of glucose intolerance and cardiovascular diseases, 
albeit through undefined mechanisms. With the aim of gaining insights into the latter, this study examined the meta‑
bolic profile of young adult male rats that were exposed to chronic unpredictable stress.
Methods: Young adult male rats were submitted to 4 weeks of chronic unpredictable stress and allowed to recover 
for 5 weeks. An extensive analysis including of morphologic, biochemical and molecular parameters was carried out 
both after chronic unpredictable stress and after recovery from stress.
Results: After 28 days of chronic unpredictable stress (CUS) the animals submitted to this protocol displayed less 
weight gain than control animals. After 5 weeks of recovery the weight gain rebounded to similar values of controls. 
In addition, following CUS, fasting insulin levels were increased and were accompanied by signs of impaired glucose 
tolerance and elevated serum corticosteroid levels. This biochemical profile persisted into the post‑stress recovery 
period, despite the restoration of baseline corticosteroid levels. The mRNA expression levels of peroxisome prolifera‑
tor‑activated receptor (PPAR)‑γ and lipocalin‑2 in white adipose tissue were, respectively, down‑ and up‑regulated.
Conclusions: Reduction of PPAR‑γ expression and generation of a pro‑inflammatory environment by increased 
lipocalin‑2 expression in white adipose tissue may contribute to stress‑induced glucose intolerance.
Keywords: Chronic unpredictable stress, Glucose intolerance, Metabolic syndrome, PPAR, Lipocalin‑2, White adipose 
tissue
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Background
Stress is a state of threatened homeostasis that triggers a 
spectrum of adaptive responses to re-establish homeo-
stasis [1]. While initially essential for survival, the physio-
logical responses to stress are detrimental to health when 
activated over a prolonged period. Epidemiological stud-
ies show that chronic stress increases the risk of diabe-
tes and metabolic syndrome [2]. However, the biological 
mechanisms underlying these associations are still not 
well understood.
Increases in corticosteroid secretion have long been 
considered to have a causal role in glucose intolerance 
associated with stress [3, 4]. These hormones enhance 
hepatic gluconeogenesis, inhibit the secretion and action 
of insulin, promote differentiation and proliferation of 
adipocytes, redistribution of fat, and decrease lipopro-
tein–lipase activity [5, 6]. However, other mechanisms 
beyond the direct effects of glucocorticoids are impli-
cated in the pathophysiology of glucose intolerance (for 
review see [7]). The overactivation of the sympathetic 
system and the promotion of a pro-inflammatory state 
in the adipose tissue [8] are common features of insulin 
resistance [9–12]. Adipose tissue inflammation is charac-
terized by macrophage infiltration and expression of pro-
inflammatory mediators such as lipocalin-2 (Lcn2) [13], 
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tumor necrosis factor-α (TNF-α), interleukin (Il)-1, Il-6, 
and chemoattractant molecules, such as monocyte che-
moattractant protein-1 (Mcp-1) [14]).
In fact, adipocytes are important players in energy 
expenditure and endocrine homeostasis [15]. In the 
center of this regulation is the proliferation-activated 
receptor (PPAR)-γ, a nuclear receptor produced mainly 
by adipocytes [16]. When activated, PPAR-γ up-regulates 
the transcription of genes mainly involved in fatty acid 
metabolism and triglyceride storage, promoting adipo-
genesis and lipids uptake to the adipose tissue [17, 18] 
improving whole body insulin sensitivity.
This study aims to unveil biological markers that estab-
lish the molecular basis of stress-induced glucose intol-
erance, with a special emphasis on the visceral white 
adipose tissue (vWAT). We extended our analysis to a 
period of recovery following chronic exposure to stress, 
an aspect often overlooked although of potential impor-




Wistar Han male rats (Charles River Laboratories, Barce-
lona, Spain), aged 2 months at arrival, were used. To avoid 
the stress of single housing, animals were housed in pairs, 
under standard laboratory conditions: artificial light–dark 
cycle of 12 h (lights from 8:00 a.m. to 8:00 p.m.) in a tem-
perature—(22  °C) and humidity (55  %) controlled room; 
animals had ad  libitum access to food (3  % of calories 
from lipids, diet 4RF21 GLP, Mucedola, Italy) and water.
Experimental design and chronic stress protocol
Figure 1 depicts the experimental design followed in this 
study. Briefly, weight-matched animals (n  =  24) were 
distributed equally between experimental and control 
groups. Animals assigned to the experimental group 
(n = 12) were submitted to chronic unpredictable stress 
(CUS) over 28 consecutive days. Six animals from each 
group were sacrificed (groups CUS and control) after 
this period and the remaining were sacrificed after 5 
additional weeks (groups CUS-Rec and Control-Rec). 
The protocol of CUS consisted of twice-daily random 
exposure to one of the following stressors: restraint (1 h), 
exposition to a hot air jet (30 min), overcrowding (1 h), 
strobe lights (1 h), shaking (30 min), cold water (15  °C, 
1 h) and noise (1 h). A glucose tolerance test (GTT) was 
performed on the morning after the end of the stress 
protocol (at 09:00 a.m.). The animals were fasted over-
night (12  h) to ensure uniform nutritional condition. 
Before the intraperitoneal injection of glucose, blood 
was collected by tail venipuncture for biochemical analy-
sis (hormonal measurements). Six animals from each 
group were sacrificed 48 h after the GTT so that further 
analyses would not be influenced by the glucose load or 
by the acute stress associated with the GTT. Again, the 
animals were fasted overnight and their visceral WAT 
(vWAT) and livers dissected out and snap-frozen for 
molecular analysis (Liver and vWAT). The remaining 
animals (n = 6 per group) were allowed to recover from 
CUS for 5  weeks (“recovery period”; group CUS-Rec). 
After this period a new GTT was performed and the 
blood collected as previously described. After 2 days, the 
remaining animals were sacrificed and tissues collected 
as before. All the blood was collected in conscious ani-
mals. Control and animals in “recovery” were submitted 
to gentle handling (approximately 20–30 min) on a daily 
basis.
Fig. 1 Experimental design of the study. Twenty four animals were 
equally distributed in four groups: control, CUS; control‑Rec and 
CUS‑Rec. CUS and CUS‑Rec were submitted to a protocol of chronic 
unpredictable stress. Animals allocated to control and CUS group 
were sacrificed after the chronic stress protocol period (28 days) in 
fasting conditions. The control‑Rec and CUS‑Rec were sacrificed after 
a period of 5 weeks post the stress protocol. CUS chronic unpredict‑
able stress; Rec recovery; GTT glucose tolerance test; WAT white 
adipose tissue
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Glucose tolerance test
The GTT was performed after CUS and after stress 
recovery following 12  h of fasting as previously men-
tioned. Glucose was intraperitoneally administered using 
a 30 % solution of glucose in water at a dose of 200 mg/g 
of weight. The blood was obtained by puncture of the tail 
vein and whole blood glucose levels were measured using 
a hand-held glucometer (Optium Xceed, Abbot, USA) to 
minimize the volume of blood needed. The glucose was 
measured at baseline and at 20, 40, 60 and 120 min after 
the intraperitoneal injection.
qRT‑PCR
Total RNA was extracted from frozen liver and adipose 
tissue, using TRIzol reagent (Invitrogen Corp, Carlsbad, 
CA, USA). Then, after quantification in the NanoDrop®, 
500 ng of total RNA from each sample RNA was reverse-
transcribed into first strand cDNA using iScript™ cDNA 
Synthesis Kit, as described in the manufacturer’s proto-
col (Bio-Rad Laboratories, Hercules, CA, USA). Quan-
titative real-time polymerase chain reaction (qRT-PCR) 
assays were carried out to measure the expression levels 
of PPAR-γ, PPAR-β, PPAR-α, Lcn2, Mcp-1, IL-1, TNF-
α, Cxcl-1, Cxcl-10 and LPL mRNA transcripts. Rela-
tive expression levels of mRNAs were calculated by the 
comparative threshold cycle method using hypoxanthine 
guanine phosphoribosyl transferase (Hprt) as an inter-
nal control (housekeeping gene), after confirming that 
expression of the gene was not influenced by the experi-
mental conditions.
Primer3 software was used to design the oligonucleotide 
primers for PPAR-γ (Fw: 5′-gagtttctgaccggactgtgtg-3′; Rw: 
5′-aagttggtgggccagaatgg-3′), PPAR-β, PPAR-α(Fw: 5′-aat-
gctctcgaactaga-3′, Rw: 5′-gcacaatcccctcctgcaac-3′), Lcn2 
(Fw: 5′-tcaccctgtacggaagaacc-3′; Rw 5′-tcggtgggaacagaga-
aaac-3′), Mcp-1 (Fw: 5′-tagcatccacgtgctgtctc-3′; Rw: 5′-tgct-
gctggtgattctcttg-3′), IL-1 (Fw: 5′-ggcttccttgtgcaagtgtc-3′; 
Rw: 5′-tgtcgagatgctgctgtgag-3′), TNF-α (Fw: 5′-atgggctcc-
ctctcatcagt-3′; Rw: 5′-gcttggtggtttgctacgac-3′), Cxcl-1 (Fw: 
5′-ggcttccttgtgcaagtgtc-3′; Rw:5′-tgtcgagatgctgctgtgag-3′), 
Cxcl-10 (Fw: 5′-ggcttccttgtgcaagtgtc-3′; Rw: 5′-tgtcgagat-
gctgctgtgag-3′), LPL (Fw: 5′-agaacgcatcatccgaagac-3′; Rw: 
5′-tgctcacactcacgttcaca-3′) and Hprt (Fw: 5′-gcagactttgctttc-
cttgg-3′; Rw: 5′-tccactttcgctgatgacac-3′). qRT-PCR was per-
formed on a CFX 96TM real time instrument (Bio-Rad), 
using QuantiTect SYBR Green RT-PCR reagent kit (Qia-
gen, Hamburg, Germany), according to the manufacturer’s 
instructions, using equal amounts of RNA from each sam-
ple. Product fluorescence was detected at the end of the 
elongation cycle. A single sharp peak was exhibited in all 
melting curves at a temperature characteristic of the prim-
ers used.
Immunohistochemistry
Animals were deeply anaesthetized with pentobarbital and 
transcardially perfused with saline before excision of vWAT 
surrounding the mesenterium; tissues were immersed in 
paraformaldehyde, before embedding in paraffin. Sub-
sequently 4  µm sections were cut and stained for Lcn2 
by immunohistochemistry, as described elsewhere [19]. 
Briefly, sections were deparaffinized and rehydrated prior 
to antigen retrieval with citrate buffer 10 mM. Endogenous 
peroxidases were blocked using 3 % hydrogen peroxide in 
water for 30  min before probing with primary antibody, 
anti-mouse lipocalin-2/neutrophil gelatinase-associated 
lipocalin (LCN2/NGAL) (1:400; R&D Systems, Minne-
apolis, MN, USA), diluted in PBS containing 0.3 % Triton 
X-100 (PBS-T) and 0.4  % bovine serum albumin (Sigma, 
St. Louis, MO). Thereafter, sections were incubated with 
biotinylated anti-goat secondary antibody and treated with 
streptavidin peroxidase conjugate (ABC kit; Sigma), before 
being developed with 3,3′-diaminobenzidine tetrahydro-
chloride hydrate (DAB; Sigma) and counterstaining with 
hematoxylin-eosin. An Optical (BX61, Olympus, Hamburg, 
Germany) microscope was used to analyze the samples. 
Average adipocytes density and volume were assessed using 
StereoInvestigator® software (MicroBrightField, Williston, 
VT, USA). Two sections from each animal (n = 5/group) 
were analyzed (five different fields/section). The area (µm2) 
of these fields was estimated using planimetry and adipo-
cytes were counted manually, using the fractionator probe. 
Individual adipose tissue densities were determined from 
the mean density in each frame (10/animal). The average 
volume of the adipocyte was assessed using the nucleator 
probe, a software tool to estimate the mean cell volume of 
a population, as described elsewhere [20]. The center of 
the largest cell, in all ten fields analyzed from the two sec-
tions, was selected and five isotropic rays were generated, 
proceeding outward, and the place where they intersected 
the cell’s limit was selected. The average adipocyte volume, 
of each animal, was determined as the mean of the volume 
of all the adipocytes measured (approximately 10/animal).
Hormones
Serum was frozen at −80  °C until further processing. 
ELISA assay kits were used to measure insulin (Mercodia, 
Sweden), leptin (Merck Millipore, Darmstadt, Germany) 
and adiponectin (Merck Millipore). Corticosterone was 
measured using a radioimmunoassay assay (MP Biomedi-
cals, Santa Ana, CA, USA). Cholesterol was measured 
by an enzymatic-colorimetric assay (Spinreact, Girona, 
Spain). All procedures were performed following the rec-
ommendations of the manufacturers. The blood used to 
perform these measurements was collected at the time 0 
of the GTT and after a period of 12 h of fasting.
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Statistical analysis
Results are expressed as mean  ±  standard deviation 
of the mean. A repeated measures analysis of variance 
(ANOVA) was performed to determine the effects 
of the variables ‘time’ and ‘group’ in both weight and 
GTT. A Bonferroni post hoc test was performed when-
ever significant interactions were found. A two-tailed 
Student’s t test was used to compare means of each 
experimental group with the respective control group 
when applied. Real time PCR results are expressed in 
fold-change compared with the control group at that 
the respective time-point. All analyses were performed 
using Statistical Pack for Social Sciences v.22 (SPSS) 
and Prism 6.
Results
Stress induces a decrease in body weight gain 
without altering food intake
A significant effect of both ‘time’ and ‘group’ was 
observed in the weight gain during the period of stress 
(Fig.  2a; p  <  0.05). This means that the CUS-treated 
group showed lower body weight gain over the 4 weeks 
of CUS when compared with control animals (Fig.  2c, 
p  <  0.05). During recovery from stress, however, previ-
ously stressed animals gained more weight than controls 
(Fig. 2c, p < 0.05) and the group effect was lost in body 
weight gain (Fig.  2b; p =  0.88). Interestingly, no signifi-
cant difference was registered in the total amount of food 
ingested by control, CUS or post-CUS recovery groups 
(Fig. 2d).
Persistent glucose intolerance phenotype induced 
by stress
Animals submitted to CUS displayed significantly higher 
serum levels of corticosterone as compared to control 
(Fig. 3a; p < 0.05). Following a 5-week stress-free period, 
corticosterone levels were similar in both CUS-Rec and 
control groups (Fig. 3a; p > 0.05).
Several parameters were monitored to assess endocrine 
and glucose homeostasis. A significant effect of both 
‘time’ and ‘group’ was observed for the GTT after stress 
(Fig.  3c: F (1.11)  =  27.02; p  <  0.05) and after recovery 
Fig. 2 Weight gain and food ingestion. CUS‑submitted animals gained less weight during the stress protocol (a ANOVA (group), F(1.11) = 10.81; 
p < 0.05) but gained more weight than controls during the recovery phase (b ANOVA, F(1.5) = 0043, p > 0.05 and c). These variations occurred 
without significant variations in food ingestion (d). CTL controls; CUS chronic unpredictable stress. *p < 0.05; **p < 0.01
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(Fig.  3d: F(1.4)  =  8.21; p  <  0.05). This means that the 
CUS-treated animals displayed higher levels of glucose 
during the GTT, both after stress and after recovery. This 
result was corroborated by the analysis of the area under 
the curve (Fig. 3b; p < 0.05).
Consistent with the glucose intolerance profile of CUS-
treated animals, insulin levels were significantly higher in 
CUS vs. control animals (Fig. 3e; p < 0.05). Plasma insulin 
levels were also higher in CUS-Rec when compared with 
control animals (Fig. 3e; p < 0.05).
Total blood cholesterol levels did not differ between 
groups (Fig. 3f; p > 0.05). Likewise, as shown in Fig. 3g, 
serum leptin levels were neither affected in CUS 
(p > 0.05) nor in the CUS-Rec groups (p > 0.05). Serum 
levels of adiponectin were also not influenced by any of 
the treatments (Fig. 2h; p > 0.05).
Persistent decreased expression of PPARγ in vWAT 
after CUS
The next task of this study was to characterize the 
transcription of molecules potentially involved in the 
pathophysiology of glucose intolerance in the vWAT. 
A significant decrease in PPAR-γ mRNA levels was 
observed in vWAT in both CUS (Fig.  4a; p  <  0.05) and 
CUS-Rec (Fig. 4a; p < 0.05). No changes were observed 
in PPARγ mRNA levels in liver after stress (Fig.  4b; 
p > 0.05) and after stress recovery (Fig. 4b). CUS did not 
significantly alter PPAR-β and -α mRNA levels in vWAT 
(Fig.  4c, f, respectively) but increased PPAR-β expres-
sion in the liver (Fig. 4d, p < 0.05) although this effect was 
reversed after recovery (Fig. 4d; p > 0.05). Expression of 
PPAR-α mRNA in the liver was neither affected by CUS 
nor CUS-Rec (Fig. 4f ). We also evaluated the transcrip-
tion of PPAR-γ target genes such as lipoprotein lipase 
(LPL), whose expression did not display significant differ-
ences (Fig. 5a).
Increased expression of LCN2 in vWAT after CUS
As previously mentioned, vWAT inflammation and the 
expression of pro-inflammatory cytokines in this tissue 
have been shown to be involved in the pathophysiology 
of insulin resistance. As so we quantified the expression 
of several pro-inflammatory and chemoattractant mol-
ecules. Comparison of vWAT from control, CUS and 
CUS-Rec revealed that, relative to the control condition, 
CUS resulted in a significant increase in Lcn2 mRNA 
levels (Fig.  5b; p  <  0.05), and that Lcn2 expression was 
restored to control levels after recovery (Fig. 5a; p > 0.05). 
Immunohistochemical analysis showed the presence of 
infiltrates of mononuclear inflammatory cells, mainly 
composed by macrophages and monocytes (Fig.  5h, 
inset); and also the presence of Lcn2 protein-positive 
inflammatory cells in vWAT from CUS-treated animals 
(Fig. 5h). In contrast, Lcn2-positive cells were not detect-
able in vWAT from CUS-Rec animals (Fig.  5h). In spite 
of the observation of macrophage infiltration of adipo-
cytes from CUS-exposed animals, this was not accompa-
nied by increased expression of inflammatory (IL-1 and 
TNFα) or key chemoattractant proteins such as Cxcl-1, 
Cxcl-10 and Mcp-1 (Fig. 5c–f). Lastly, adipocyte volume 
and cell density did not differ between the control, CUS 
and CUS-Rec groups (Table 1).
Discussion
This study reproduced the phenomenon of stress-induced 
glucose intolerance, characterized by higher levels of basal 
insulin and higher levels of glucose during the GTT. This 
phenotype was accompanied by a decrease in the expres-
sion of PPAR-γ, an increase in the expression of Lcn2 in 
the vWAT, and an increase in the morning levels of corti-
costerone. Interestingly, while the expression of Lcn2 and 
the levels of corticosterone normalized after recovery, the 
glucose intolerance phenotype and the lower expression 
of PPAR-γ prevailed after 5 weeks of recovery from stress.
Previous studies had already examined the relationship 
between stress and glucose intolerance, using different 
paradigms of chronic stress and diets [21–29]. To avoid the 
latter as a confounding factor, we studied the effects of CUS 
in animals that only had access to regular chow. Interest-
ingly, our CUS-treated rats displayed hyperinsulinemia and 
glucose intolerance in spite of having less body weight than 
controls. On contrary to other studies [29], the differences 
in weight occurred without alterations in food ingestion 
supporting the idea that stress promotes a hypercatabolic 
state [25]. Unfortunately, the housing of two animals/cage 
to avoid the confounding factor of isolation stress [30], pre-
cluded the analysis of individual food consumption rates. 
Moreover, the alterations in weight gain were not accom-
panied by differences in adipocyte size in the vWAT or 
differences in the serum levels of leptin, adiponectin or 
cholesterol. The serum level of these hormones was altered 
in studies where chronic stress was administered together 
(See figure on previous page.) 
Fig. 3 Glucose homeostasis and adipokines in blood. Corticosterone was significantly elevated in animals exposed to CUS but returned to basal 
levels after recovery (a). CUS‑submitted animals displayed an glucose intolerance profile that persisted after recovery, characterized by higher levels 
of glucose in the GTT (b area under the curve; c, d plot at specific timepoints) and hyperinsulinemia (e). No differences were found in cholesterol 
(f), leptin (g) or adiponectin (h) between controls, CUS and CUS after recovery. AUC area under the curve; CTL controls; CUS chronic unpredictable 
stress. GTT glucose tolerance test. *p < 0.05; **p < 0.01
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with energy-rich diets [31]. This highlights the fact that 
altered glucose intolerance may be the primary mechanism 
through which stress disrupts metabolism.
Another important observation of our study was that 
CUS-induced glucose intolerance persisted for 5  weeks 
after the stress protocol. The long-lasting metabolic 
effects of CUS were also shown in the adult offspring of 
stressed pregnant females [32]. Importantly, following 
recovery from CUS, glucocorticoid levels were restored to 
those found in control animals as well as the expression 
Fig. 4 Expression of peroxisome proliferator‑activated receptors (PPAR). Animals submitted to CUS displayed a lower expression of PPAR‑γ mRNA 
quantified by real‑time PCR in the white adipose tissue (vWAT) both after stress and after recovery (a). No differences were found in the expression 
of PPAR‑γ mRNA in the liver (b). The expression of PPAR‑β was similar between CUS and the controls in the vWAT (c), while in the liver the expres‑
sion of PPAR‑β was elevated in CUS after stress returning to basal levels after recovery (d). No differences were found in the expression of PPAR‑α 
between CUS and controls neither in the vWAT (e) nor in the liver (f). CTL controls; CUS chronic unpredictable stress; PPAR peroxisome proliferator‑
activated receptors. *p < 0.05; **p < 0.01
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of Lcn2 in the vWAT. Thus, the direct effect of glucocor-
ticoids on the levels of glucose cannot be the explanation 
for the glucose intolerance found in CUS-Rec. At this 
level PPARs may play a crucial role.
As previously mentioned, PPAR-γ up-regulates the tran-
scription of genes mainly involved in fatty acid metabolism 
and triglyceride storage, promoting adipogenesis and 
lipids uptake to the adipose tissue [17, 18]. These events 
decrease the serum levels of free fatty acids and induce 
a lipid repartitioning from the skeletal muscle and liver 
to the adipose tissue, thus eliminating the deleterious 
effects of lipids on insulin signaling [17, 18]. Matsusue 
Fig. 5 Expressome and Morphologic analyses of the white adipose tissue. The expression of Lcn2 mRNA quantified by real‑time PCR was signifi‑
cantly increased in animals submitted to CUS in the white adipose tissue and returned to basal levels after the recovery period (a). No differences 
were found in the expression of TNF‑α, IL‑1, Mcp‑1, Cxcl‑1 or Cxcl‑10 in vWAT (b–g). h shows the immunohistochemistry of vWAT. It revealed the 
presence of Lcn2 positive mononuclear inflammatory cells in CUS‑submitted animals (h), mainly composed by macrophages and monocytes (inset); 
and also the presence of Lcn2 protein‑positive inflammatory cells in CUS group after stress (red arrow). These findings reverted after recovery. CUS 
chronic unpredictable stress; Cxcl chemokine (C‑X‑C motif ) ligand; IL interleukin; Lcn2 lipocalin‑2; LPL lipoprotein lipase; Mcp‑1 monocyte chemoat‑
tractant protein‑1; TNF‑α tumor necrosis factor‑α; *p < 0.05; **p < 0.01
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and colleagues showed that, in diabetic obese mice with 
liver-specific PPAR-γ deletion, thiazolidinediones (a full 
PPAR-γ agonist) remained effective in lowering glucose 
levels, contradicting the hypothesis that liver PPAR-γ was 
the responsible for the insulin sensitization effects of these 
drugs [33]. Accordingly, our results show that CUS caused 
a selective downregulation of PPAR-γ mRNA expression 
in vWAT that persisted after recovery. This indicates that 
vWAT is an important target tissue of stress and that the 
disruption of PPAR-γ signaling may be responsible for the 
perpetuation of glucose intolerance after CUS recovery. 
PPAR-γ is mainly expressed in the adipose tissue and only 
in a small amount in the liver (in our data, control animals 
displayed an expression of PPAR-γ in the vWAT approxi-
mately 5 times superior to the expression in the liver). This 
may justify the selective downregulation of PPAR-γ in the 
adipose tissue. Interestingly, in cardiomyocytes the regu-
lation of PPAR signaling was also shown to be involved 
in the pathophysiology of diabetic cardiomyopathy [34]. 
The evidence concerning modulation of PPAR-γ expres-
sion by glucocorticoids is still very scarce but it is of notice 
that few experiments in adipocytes show that PPAR-γ is 
responsive to glucocorticoids [35, 36]. This supports the 
idea that glucocorticoid-induced disruption of PPAR-γ 
signaling may underlie stress-induced glucose intoler-
ance. We did not find statistically significant differences in 
the expression of LPL (which is a target gene of PPAR-γ) 
among groups. This may be explained by the fact that 
LPL is regulated by other mediators that not only PPAR-γ. 
Beside its effects on lipid metabolism, PPAR-γ activation 
also exerts anti-inflammatory activity by suppressing the 
production of inflammatory mediators as IL-6, plasmino-
gen activator inhibitor-1, Mcp-1 and TNFα [37].
In recent years, the importance of adipose tissue 
inflammation has gained increasing attention, as a 
result of studies showing a clear association between 
inflammation and insulin resistance [38]. In general, 
pro-inflammatory cytokines produced in the adipose 
tissue promote insulin resistance mainly by promoting 
lipolysis and disruption of the insulin and leptin sign-
aling in skeletal muscle and liver [39]. Surprisingly we 
did not observe differences in the expression of pro-
inflammatory or chemoattractant cytokines after CUS 
(as previously described by others [27, 40]). Instead, we 
showed that CUS elicited only a very significant over-
expression of Lcn2, which is considered an acute-phase 
response protein [41]. This was accompanied by the 
appearance of Lcn2 positive cells infiltrating the adi-
pose tissue. From a clinical perspective Lcn2 has been 
validated as a useful marker of metabolic syndrome 
[42] and has been implicated in the pathophysiology 
of insulin resistance by antagonizing the detrimental 
effects of inflammatory molecules (in particular TNFα) 
on the metabolism of adipocytes and macrophages, 
mainly through the modulation of PPAR-γ expression 
[43]. Lcn2 was also shown to be a selective modulator 
of PPAR-γ activation, being necessary to its full activa-
tion by thiazolidinediones, due to their interaction at 
the level of the recruitment of coactivators/corepres-
sors [41]. In spite of these observations, which were 
partially derived from in vitro studies, Lcn2 was found 
to be overexpressed in the adipose tissue of obese 
animals [43]. However, conflicting results have been 
described regarding (increased or decreased) glucose 
intolerance in Lcn2 knockout mice [44, 45]. Together 
with human studies, the general consensus is that Lcn2 
is overexpressed during insulin resistance. Of note, this 
Lcn2 overexpression may be driven by glucocorticoids 
since Lcn2 has a glucocorticoid response element [46]. 
Interestingly, elevated adipose tissue Lcn2 levels can 
be normalized by the insulin-sensitizing drug rosiglita-
zone reinforcing the interconnection between PPAR-γ 
and this molecule [43]. In spite of this evidence the fact 
is that the levels of PPAR-γ remain low while the levels 
of Lcn2 return to normal after recovery. This suggests 
that there are other mechanisms regulating the expres-
sion of Lcn2 and PPAR-γ. Given the presence of Lcn2 
positive infiltrating cells after stress we may speculate 
that the origin of the overexpression of Lcn2 is not 
coming from the adipocyte itself but rather from mac-
rophages infiltrating the adipose tissue. Despite these 
results it is still a matter of debate whether this Lcn2 
overexpression is beneficial or detrimental to the glu-
cose intolerance phenotype.
In this study, we did not explore other potential path-
ways through which an association between stress and 
glucose intolerance can be established. Specifically, sev-
eral studies suggest that the disruption of nitric oxide 
pathway [47, 48] and oxidative stress [40] may also con-
tribute to stress-related glucose intolerance and vascu-
lar dysfunction. Another limitation of this study was the 
lack of a more thoroughly analysis of the insulin signaling 
to determine if the glucose intolerance reported here is 
associated with insulin resistance.
Table 1 Volume and density of the adipocytes in the white 
adipose tissue
No differences were found in the volume and density of adipocytes between 
chronic stress and controls both after stress and after recovery
CUS chronic unpredictable stress
After stress After recovery
Controls CUS Controls CUS
Volume (×105 μm3) 47.8 ± 13.4 45.5 ± 12.7 74.4 ± 13.4 64.1 ± 18.7
Density (×10−4) 5.3 ± 1.0 4.8 ± 1.0 3.2 ± 0.8 3.74 ± 1.1
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Conclusion
In summary, our experimental work shows that the 
metabolic effects of chronic stress persist after a period 
of recovery and that the glucose intolerance triggered by 
chronic stress is associated with a decrease in the expres-
sion of PPAR-γ and a transient overexpression of Lcn2 in 
the vWAT. The characterization of the mechanistic path-
ways of stress-related disorders will significantly contrib-
ute to the design of appropriate interventions for patients 
suffering from these conditions (e.g. depression or anxi-
ety). Concerning the glucose intolerance we believe that 
in a near future, new experiments using pharmacological 
approaches (e.g. thiazolidinediones) will shed more light 
into this topic.
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